266 related articles for article (PubMed ID: 22004414)
1. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.
Rockey WM; Hernandez FJ; Huang SY; Cao S; Howell CA; Thomas GS; Liu XY; Lapteva N; Spencer DM; McNamara JO; Zou X; Chen SJ; Giangrande PH
Nucleic Acid Ther; 2011 Oct; 21(5):299-314. PubMed ID: 22004414
[TBL] [Abstract][Full Text] [Related]
2. Structural computational modeling of RNA aptamers.
Xu X; Dickey DD; Chen SJ; Giangrande PH
Methods; 2016 Jul; 103():175-9. PubMed ID: 26972787
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.
Ptacek J; Zhang D; Qiu L; Kruspe S; Motlova L; Kolenko P; Novakova Z; Shubham S; Havlinova B; Baranova P; Chen SJ; Zou X; Giangrande P; Barinka C
Nucleic Acids Res; 2020 Nov; 48(19):11130-11145. PubMed ID: 32525981
[TBL] [Abstract][Full Text] [Related]
4. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
Lupold SE; Hicke BJ; Lin Y; Coffey DS
Cancer Res; 2002 Jul; 62(14):4029-33. PubMed ID: 12124337
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
7. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
8. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe.
Min K; Song KM; Cho M; Chun YS; Shim YB; Ku JK; Ban C
Chem Commun (Camb); 2010 Aug; 46(30):5566-8. PubMed ID: 20407731
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Dassie JP; Liu XY; Thomas GS; Whitaker RM; Thiel KW; Stockdale KR; Meyerholz DK; McCaffrey AP; McNamara JO; Giangrande PH
Nat Biotechnol; 2009 Sep; 27(9):839-49. PubMed ID: 19701187
[TBL] [Abstract][Full Text] [Related]
11. In silico designed RNA aptamer against epithelial cell adhesion molecule for cancer cell imaging.
Bavi R; Liu Z; Han Z; Zhang H; Gu Y
Biochem Biophys Res Commun; 2019 Feb; 509(4):937-942. PubMed ID: 30648555
[TBL] [Abstract][Full Text] [Related]
12. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
Kim D; Jeong YY; Jon S
ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
[TBL] [Abstract][Full Text] [Related]
13. Screening and characterization of a novel RNA aptamer that specifically binds to human prostatic acid phosphatase and human prostate cancer cells.
Kong HY; Byun J
Mol Cells; 2015; 38(2):171-9. PubMed ID: 25591398
[TBL] [Abstract][Full Text] [Related]
14. Computer-aided design of aptamers for cytochrome p450.
Shcherbinin DS; Gnedenko OV; Khmeleva SA; Usanov SA; Gilep AA; Yantsevich AV; Shkel TV; Yushkevich IV; Radko SP; Ivanov AS; Veselovsky AV; Archakov AI
J Struct Biol; 2015 Aug; 191(2):112-9. PubMed ID: 26166326
[TBL] [Abstract][Full Text] [Related]
15. RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.
Mittelberger F; Meyer C; Waetzig GH; Zacharias M; Valentini E; Svergun DI; Berg K; Lorenzen I; Grötzinger J; Rose-John S; Hahn U
RNA Biol; 2015; 12(9):1043-53. PubMed ID: 26383776
[TBL] [Abstract][Full Text] [Related]
16. Investigations on the interface of nucleic acid aptamers and binding targets.
Cai S; Yan J; Xiong H; Liu Y; Peng D; Liu Z
Analyst; 2018 Nov; 143(22):5317-5338. PubMed ID: 30357118
[TBL] [Abstract][Full Text] [Related]
17. The use of aptamers in prostate cancer: A systematic review of theranostic applications.
Campos-Fernández E; Oliveira Alqualo N; Moura Garcia LC; Coutinho Horácio Alves C; Ferreira Arantes Vieira TD; Caixeta Moreira D; Alonso-Goulart V
Clin Biochem; 2021 Jul; 93():9-25. PubMed ID: 33794195
[TBL] [Abstract][Full Text] [Related]
18. Method for Confirming Cytoplasmic Delivery of RNA Aptamers.
Dickey DD; Thomas GS; Dassie JP; Giangrande PH
Methods Mol Biol; 2016; 1364():209-17. PubMed ID: 26472453
[TBL] [Abstract][Full Text] [Related]
19. Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing.
Berezhnoy A; Stewart CA; Mcnamara JO; Thiel W; Giangrande P; Trinchieri G; Gilboa E
Mol Ther; 2012 Jun; 20(6):1242-50. PubMed ID: 22434135
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.
Dassie JP; Hernandez LI; Thomas GS; Long ME; Rockey WM; Howell CA; Chen Y; Hernandez FJ; Liu XY; Wilson ME; Allen LA; Vaena DA; Meyerholz DK; Giangrande PH
Mol Ther; 2014 Nov; 22(11):1910-22. PubMed ID: 24954476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
